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The history of Myology in Italy begins in 16th century with 
muscle anatomy pictures by Vesalius and Canani while in the 
19th century the Neapolitan physician Gaetano Conte described 
Duchenne muscular dystrophy on clinical basis (1).
Myology reached a major development in the 20th century 
with the establishment of the CNR center in Padova (professor 
Massimiliano Aloisi) a cardiomyological and genetic center in 
Naples (professor Giovanni Nigro) and a neurological center in 
Milan (professor Guglielmo Scarlato). In the 60th prof. Aloisi and 
Federico Milcovich, a myodystrophic patient, started the Italian 
Muscular Dystrophy patients association (UILDM) with contacts 
with MDA (2). The first congress in Neuromuscular diseases took 
place in Milan in 1969 by the organization of professor Scarlato, 
Aloisi, Canal and was attended by several outstanding internation-
al muscle researchers such as AG Engel, WK Engel, LP Rowland, 
M.Fardeau and I.Hausmanowa-Petrusewicz. Eleven meetings in 
many countries followed this, up to the last XII international Con-
gress on Neuromuscular Diseases in Naples in 2010.
Several laboratories arose in the country especially in Neu-
rological Institutes; several researchers emigrated permanently 
or went for a stage to improve their myological skills especially 
in USA, UK, Canada, France both in basic and/or pathological, 
clinical research (Table 1). The laboratory of Columbia in New 
York, lead by professor Di Mauro was a common place of train-
ing especially in the field of mitochondrial myopathies.
As in other developed countries, the basis of neuromuscular 
research and diagnosis were expanded on immunohistochemi-
cal, biochemical and molecular grounds, during the 20th and the 
beginning of the 21st century. Enzo Ferrari – a race car factory 
engineer – was a support to research in muscular dystrophy in 
Milan, Padova and Modena. Telethon has contributed to sup-
port in neuromuscular disorders. Myology with the enlargement 
of scientific basis in the molecular era began to split in sub-
specialities i.e. genetics, physiopathology etc. and a spectrum of 
knowledge was accumulated both for diagnostic and therapeu-
tic purposes. In the field of metabolic diseases and limb-girdle 
myopathies several Italian laboratories described new entities. 
A number of treatments, beside the treatment of inflammatory 
myopathies and myasthenia gravis, were found and applied in 
metabolic myopathies: i.e. carnitine, Coenzyme Q, enzyme re-
placement in glycogenosis type II.
The continuous challenge of the treatment of the primary 
muscular dystrophy remains for the future since so far there are 
only emerging molecular therapies: antisense oligonucleotides 
in DMD, adenoviral therapy in sarcoglycanopathies, cell therapy 
might contribute to answer to a promises for muscular patients.
In the translation area many laboratories and Italian groups 
continue  with  new  researchers  and  they  have  contributed  to 
meetings of European Neuromuscular Center and to the Foun-
dation and organisation of the World Muscle Society with meet-
ings in Italy (Naples, Taormina), and to the Treat – NMD and 
Eurobiobank networks.
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The metabolic myopathies are thought to be more amena-
ble to treatment once the defect in the biochemical pass way is 
identified. Some of the defects cause mainly exercise intoler-
ance and its improvement can be regarded as therapeutic suc-
cess. In others muscle weakness and degeneration is seen and 
functional and strength improvement is the goal.
Therapy  of  such  muscle  metabolic  disorders  can  be 
achieved  through  enzyme  replacement,  e.g.  therapy  of  acid 
maltase deficiency (Pompe’s disease) which is currently admin-
istered to young and adult patients. Enzyme upregulation can 
also be attempted and a case in point is bezafibrate in carnitine 
palmityl transferase 2 deficiency.
Lectures by invited speakers
Table 1. The main international connections.
USA - Mayo Clinic (Engel AG): Angelini, Mora, Milone, 
Fumagalli
USA - Children Hospital (Hoffmann): Pegoraro, Gorni
USA - USC Los Angeles (Engel WK, Askanas): Martinuzzi, 
Vita, Broccolini, Mirabella, Vattemi
USA - Columbia University (Rowland, Di Mauro): Trevisan, 
Bresolin, Bruno, Mancuso, Zeviani, Servidei, Ricci, Minetti, 
Moggio, Musumeci, Salviati.
Canada - Montreal (Karpati): Armani
UK - London (Dubowitz): Muntoni, Mercuri, Sorarù
UK - London (Morgan-Hughes): Toscano
UK - Newcastle (Walton, Bushby): Vita, Guglieri
UK - Oxford (Vincent): Evoli
UK - Liverpool (Edwards): Siciliano
France - Paris (Fardeau, Tomè): Villanova, Berardinelli
France - Nice (Desnuelle): Sacconi
France - Poitiers (Rideau): Nigro, Comi, Politano, Bianchi
Poland –Warsaw (Hausmanowa-Petrusewicz): (Nigro, Comi, 
Petretta, Politano)